Biden needs to stand with kids and get schools open as he promised
Truths about vaccine timetable and other commentary
Thousands of COVID vaccination slots still unclaimed at Yankee Stadium
NY rejects de Blasio’s request to tap into COVID-19 vaccine reserves
Pharmaceutical giant Johnson & Johnson on Thursday filed for emergency authorization of its one-dose COVID-19 vaccine.
The company’s inoculation is 66 percent effective against moderate to severe cases of the deadly global pandemic, but it only requires a single dose and offers strong protection against hospitalization and death from the bug, Politico reported.
The J&J vaccine would add a vital third option — along with Pfizer and Moderna shots — as the US struggles to distribute vaccines against the coronavirus, which has killed more than 455,000 Americans, according to Johns Hopkins University, which is tracking the virus.
However, the J&J version has proved less effective against a more aggressive strain of the virus found in South Africa, the report said.
That strain, as well as a variant identified in the UK, has been detected in the US.
Nonetheless, the J&J vaccine provides a third line of defense.
“Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping,” Paul Stoffels, the company’s chief scientific officer, said in a statement. “We are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”